HCA
HCA
HCA Healthcare, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $19.11B ▼ | $0 ▼ | $1.62B ▼ | 8.48% ▼ | $7.15 ▼ | $3.79B ▼ |
| Q4-2025 | $19.51B ▲ | $5B ▼ | $1.88B ▲ | 9.62% ▲ | $8.14 ▲ | $4.16B ▲ |
| Q3-2025 | $19.16B ▲ | $5.05B ▲ | $1.64B ▼ | 8.57% ▼ | $7.05 ▲ | $3.87B ▲ |
| Q2-2025 | $18.61B ▲ | $4.66B ▼ | $1.65B ▲ | 8.88% ▲ | $6.91 ▲ | $3.85B ▲ |
| Q1-2025 | $18.32B | $4.71B | $1.61B | 8.79% | $6.52 | $3.73B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $940M ▼ | $61.45B ▲ | $64.43B ▲ | $-6.3B ▼ |
| Q4-2025 | $1.04B ▲ | $60.72B ▲ | $63.49B ▲ | $-6.03B ▼ |
| Q3-2025 | $997M ▼ | $59.75B ▲ | $61.91B ▲ | $-5.33B ▼ |
| Q2-2025 | $1.04B ▼ | $59.54B ▼ | $60.77B ▲ | $-4.39B ▼ |
| Q1-2025 | $1.06B | $59.8B | $60.24B | $-3.52B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.62B ▼ | $2.01B ▼ | $-1.28B ▲ | $-830M ▲ | $-100M ▼ | $895M ▲ |
| Q4-2025 | $1.88B ▲ | $2.36B ▼ | $-1.32B ▲ | $-999M ▲ | $43M ▼ | $870M ▼ |
| Q3-2025 | $1.64B ▼ | $4.42B ▲ | $-1.39B ▼ | $-2.97B ▲ | $58M ▲ | $3.13B ▲ |
| Q2-2025 | $1.89B ▲ | $4.21B ▲ | $-1.25B ▼ | $-3.09B ▼ | $-121M ▲ | $3.03B ▲ |
| Q1-2025 | $1.82B | $1.65B | $-1.03B | $-1.5B | $-873M | $660M |
Revenue by Products
| Product | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
International | $460.00M ▲ | $480.00M ▲ | $470.00M ▼ | $500.00M ▲ |
Managed Care And Other Insurers | $9.12Bn ▲ | $9.27Bn ▲ | $9.54Bn ▲ | $9.08Bn ▼ |
Managed Medicaid | $900.00M ▲ | $950.00M ▲ | $970.00M ▲ | $940.00M ▼ |
Managed Medicare | $3.35Bn ▲ | $3.31Bn ▼ | $3.48Bn ▲ | $3.51Bn ▲ |
Medicaid | $1.44Bn ▲ | $1.78Bn ▲ | $1.50Bn ▼ | $1.44Bn ▼ |
Medicare | $2.80Bn ▲ | $2.73Bn ▼ | $2.85Bn ▲ | $3.06Bn ▲ |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
American Group | $6.49Bn ▲ | $6.69Bn ▲ | $6.93Bn ▲ | $6.57Bn ▼ |
Atlantic Group | $6.12Bn ▲ | $6.14Bn ▲ | $6.28Bn ▲ | $6.36Bn ▲ |
National Group | $5.20Bn ▲ | $5.53Bn ▲ | $5.49Bn ▼ | $5.32Bn ▼ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at HCA Healthcare, Inc.'s financial evolution and strategic trajectory over the past five years.
HCA combines accelerating revenue growth with improving profitability and strong cash generation. Its scale and dense network across many markets give it significant negotiating power and operating leverage. The company has a clear edge in data and analytics, reinforced by proprietary AI‑driven tools and a strategic partnership with Google Cloud. Ownership of Galen College of Nursing offers a unique solution to labor constraints, and rising free cash flow supports both substantial reinvestment in facilities and technology and meaningful returns of capital to shareholders.
The main financial risks center on leverage and liquidity. Debt levels and net debt have increased steadily, while shareholders’ equity has turned negative and retained earnings have been drawn down by heavy capital returns, leaving less of a balance‑sheet cushion. Liquidity ratios remain tight, so the company depends heavily on continued strong cash generation and access to capital markets. Operationally, HCA must navigate industry‑wide challenges such as labor shortages, wage pressures, regulatory uncertainty, and competition from both large systems and specialized providers. There is also execution risk around scaling complex technology and AI initiatives across such a large organization.
Based on the provided information, HCA appears to be a fundamentally strong operator with an improving income statement, robust cash flows, and a sophisticated innovation agenda, but with a more aggressive balance‑sheet posture than many peers. If management continues to translate its scale, technology investments, and nursing pipeline into better margins and cash flow, the company is well positioned to benefit from growing healthcare demand and the shift toward data‑driven care. However, the combination of high leverage, tight liquidity, and sector headwinds means that the forward path is not without risk, and future performance will hinge on disciplined capital allocation and successful execution of its operational and technology strategies.
About HCA Healthcare, Inc.
https://www.hcahealthcare.comHCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $19.11B ▼ | $0 ▼ | $1.62B ▼ | 8.48% ▼ | $7.15 ▼ | $3.79B ▼ |
| Q4-2025 | $19.51B ▲ | $5B ▼ | $1.88B ▲ | 9.62% ▲ | $8.14 ▲ | $4.16B ▲ |
| Q3-2025 | $19.16B ▲ | $5.05B ▲ | $1.64B ▼ | 8.57% ▼ | $7.05 ▲ | $3.87B ▲ |
| Q2-2025 | $18.61B ▲ | $4.66B ▼ | $1.65B ▲ | 8.88% ▲ | $6.91 ▲ | $3.85B ▲ |
| Q1-2025 | $18.32B | $4.71B | $1.61B | 8.79% | $6.52 | $3.73B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $940M ▼ | $61.45B ▲ | $64.43B ▲ | $-6.3B ▼ |
| Q4-2025 | $1.04B ▲ | $60.72B ▲ | $63.49B ▲ | $-6.03B ▼ |
| Q3-2025 | $997M ▼ | $59.75B ▲ | $61.91B ▲ | $-5.33B ▼ |
| Q2-2025 | $1.04B ▼ | $59.54B ▼ | $60.77B ▲ | $-4.39B ▼ |
| Q1-2025 | $1.06B | $59.8B | $60.24B | $-3.52B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.62B ▼ | $2.01B ▼ | $-1.28B ▲ | $-830M ▲ | $-100M ▼ | $895M ▲ |
| Q4-2025 | $1.88B ▲ | $2.36B ▼ | $-1.32B ▲ | $-999M ▲ | $43M ▼ | $870M ▼ |
| Q3-2025 | $1.64B ▼ | $4.42B ▲ | $-1.39B ▼ | $-2.97B ▲ | $58M ▲ | $3.13B ▲ |
| Q2-2025 | $1.89B ▲ | $4.21B ▲ | $-1.25B ▼ | $-3.09B ▼ | $-121M ▲ | $3.03B ▲ |
| Q1-2025 | $1.82B | $1.65B | $-1.03B | $-1.5B | $-873M | $660M |
Revenue by Products
| Product | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
International | $460.00M ▲ | $480.00M ▲ | $470.00M ▼ | $500.00M ▲ |
Managed Care And Other Insurers | $9.12Bn ▲ | $9.27Bn ▲ | $9.54Bn ▲ | $9.08Bn ▼ |
Managed Medicaid | $900.00M ▲ | $950.00M ▲ | $970.00M ▲ | $940.00M ▼ |
Managed Medicare | $3.35Bn ▲ | $3.31Bn ▼ | $3.48Bn ▲ | $3.51Bn ▲ |
Medicaid | $1.44Bn ▲ | $1.78Bn ▲ | $1.50Bn ▼ | $1.44Bn ▼ |
Medicare | $2.80Bn ▲ | $2.73Bn ▼ | $2.85Bn ▲ | $3.06Bn ▲ |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
American Group | $6.49Bn ▲ | $6.69Bn ▲ | $6.93Bn ▲ | $6.57Bn ▼ |
Atlantic Group | $6.12Bn ▲ | $6.14Bn ▲ | $6.28Bn ▲ | $6.36Bn ▲ |
National Group | $5.20Bn ▲ | $5.53Bn ▲ | $5.49Bn ▼ | $5.32Bn ▼ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at HCA Healthcare, Inc.'s financial evolution and strategic trajectory over the past five years.
HCA combines accelerating revenue growth with improving profitability and strong cash generation. Its scale and dense network across many markets give it significant negotiating power and operating leverage. The company has a clear edge in data and analytics, reinforced by proprietary AI‑driven tools and a strategic partnership with Google Cloud. Ownership of Galen College of Nursing offers a unique solution to labor constraints, and rising free cash flow supports both substantial reinvestment in facilities and technology and meaningful returns of capital to shareholders.
The main financial risks center on leverage and liquidity. Debt levels and net debt have increased steadily, while shareholders’ equity has turned negative and retained earnings have been drawn down by heavy capital returns, leaving less of a balance‑sheet cushion. Liquidity ratios remain tight, so the company depends heavily on continued strong cash generation and access to capital markets. Operationally, HCA must navigate industry‑wide challenges such as labor shortages, wage pressures, regulatory uncertainty, and competition from both large systems and specialized providers. There is also execution risk around scaling complex technology and AI initiatives across such a large organization.
Based on the provided information, HCA appears to be a fundamentally strong operator with an improving income statement, robust cash flows, and a sophisticated innovation agenda, but with a more aggressive balance‑sheet posture than many peers. If management continues to translate its scale, technology investments, and nursing pipeline into better margins and cash flow, the company is well positioned to benefit from growing healthcare demand and the shift toward data‑driven care. However, the combination of high leverage, tight liquidity, and sector headwinds means that the forward path is not without risk, and future performance will hinge on disciplined capital allocation and successful execution of its operational and technology strategies.

CEO
Samuel N. Hazen
Compensation Summary
(Year 2025)
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 817
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Truist Securities
Buy
TD Cowen
Buy
Oppenheimer
Outperform
RBC Capital
Outperform
Barclays
Overweight
Stephens & Co.
Overweight
Grade Summary
Showing Top 6 of 20
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:14.89M
Value:$5.64B
BLACKROCK INC.
Shares:14.85M
Value:$5.62B
BLACKROCK, INC.
Shares:13.36M
Value:$5.06B
Summary
Showing Top 3 of 1,872

